|Transcript ID (GRCh37/hg19)||ENST00000318493|
|Tumor Type||Primary Site|
Amplification of MET, the hepatocyte growth factor receptor, is identified in 7% of Esophagus-Stomach cancer in recent TCGA study. Several studies investigated the relationship between MET amplification and expression with the clinical outcome in patients with gastric cancer, but yielded conflicting results. Multiple clinical trials of using anti-MET agent in the treatment of Esophagus-Stomach cancer are available.
This gene is a known cancer gene.
MET amplification may be associated with sensitivity to MET inhibitors. MET amplification is associated with resistance to EGFR inhibitors in EGFR mutated lung cancer. MET alterations are commonly associated with papillary renal-cell carcinoma and it is very rare in clear cell renal cell carcinoma.